Amgen's MariTide Aims to Cut Obesity Shots From 52 a Year to as Few as Four

Amgen (AMGN) received FDA approval for its biosimilar KANJINTI (trastuzumab-anns) on November 9, 2026. The company's stock has shown varied reactions to past FDA approvals and other news, with a median move of 1.2% in either direction. Amgen is a biotechnology company focused on biological products.

Amgen (AMGN) presented data at the AHA Scientific Sessions 2026, showing Repatha (evolocumab) is cost-effective and reduces cardiovascular risk. Analyses found a 39% reduction in major adverse cardiovascular events in CKD patients and sustained benefits over 8 years. AMGN stock is up 1.04% to $465.23.

Amgen presented data at AHA 2026 showing Repatha's cost-effectiveness in high-risk patients without prior heart attacks or strokes, with a 29% lower risk of major cardiovascular events in ASCVD patients. The VESALIUS-CV and FOURIER trials demonstrated Repatha's long-term benefits, including a 39% reduction in MACE in CKD patients and a 29% lower rate of 3-P MACE over 8 years.

Major U.S. indices fell last week, with the Nasdaq down 3.37% and S&P 500 off 2.68%. The CBOE Volatility Index settled at 23.5. Enbridge reported Q3 earnings of $0.59 per share, Amgen saw 8% revenue growth, Thomson Reuters reported 10% revenue growth, Sun Life Financial increased underlying net income by 9%, and Eli Lilly partnered with Hims & Hers.

Novartis and Ionis reported that pelacarsen failed to reduce cardiovascular events in the HORIZON trial, despite lowering lipoprotein(a) levels. Analysts see a challenging path for Lp(a)-targeting therapies, including Amgen's olpasiran and Eli Lilly's lepodisiran. Novartis' stock was impacted, and analysts lowered success probabilities for competitors' drugs. The trial results raise questions about the viability of Lp(a) targeting in cardiovascular disease.

Amgen (AMGN) is developing MariTide, an obesity drug requiring fewer injections than competitors like Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Zepbound. Amgen's Q3 revenue rose 8% to $10.4B, with EPS up 14% to $6.45, beating estimates. The company raised its full-year EPS guidance to $22.90-$23.70. MariTide's Phase 3 trials will be critical for Amgen's long-term valuation.